Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) EBITDA Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBITDA Margin for 16 consecutive years, with 0.96% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 949.0% to 0.96% in Q3 2025 year-over-year; TTM through Sep 2025 was 53.24%, a 4468.0% decrease, with the full-year FY2024 number at 2.6%, down 212.0% from a year prior.
  • EBITDA Margin was 0.96% for Q3 2025 at Harvard Bioscience, up from 4.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 16.0% in Q4 2022 to a low of 228.11% in Q1 2025.
  • A 5-year average of 13.31% and a median of 1.2% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 2916bps in 2023, then tumbled -21881bps in 2025.
  • Harvard Bioscience's EBITDA Margin stood at 1.2% in 2021, then soared by 1436bps to 16.0% in 2022, then plummeted by -148bps to 7.63% in 2023, then soared by 301bps to 15.36% in 2024, then plummeted by -94bps to 0.96% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's EBITDA Margin are 0.96% (Q3 2025), 4.0% (Q2 2025), and 228.11% (Q1 2025).